American Gastroenterological Association and MATTER welcome 11 startups to inaugural incubator
The AGA Incubator: Improving GI Care is the first program dedicated to advancing innovation in digestive disease care.
MATTER, the premier healthcare incubator and innovation hub, and the American Gastroenterological Association (AGA), the nonprofit medical society dedicated to advancing the science and practice of gastroenterology, are proud to announce the inaugural cohort of the AGA Incubator: Improving GI Care.
This first-of-its-kind program is designed to advance the development of innovative solutions that transform digestive disease care — from improving diagnostics and patient experience to accelerating therapies. Over the next six months, participating startups will engage in tailored programming, mentorship and strategic connections to accelerate their growth and impact. The program will conclude at Digestive Disease Week® 2026 in Chicago, Illinois, where teams will showcase their progress and connect with investors, potential customers and healthcare leaders.
Learn more about the cohort:
JOGO
JOGO is a hybrid (telehealth and in-clinic) reimbursable digital surface EMG biofeedback system cleared by the FDA to retrain pelvic floor and abdominal muscle coordination for treating chronic constipation, defecation dyssynergia, fecal incontinence and IBS/IBD. JOGO enables gastroenterology clinics to add a new reimbursable revenue stream while maintaining focus on high-acuity procedures.
Luminoah Inc.
Luminoah Inc. is a med tech company based in Charlottesville, Virginia, dedicated to making enteral nutrition delivery simpler, smarter and easier for everyone.
MiWEndo Solutions
MiWEndo Solutions is a med tech company developing a microwave-based add-on device for colonoscopy, enabling real-time detection and characterization of colorectal lesions. By combining microwave imaging with AI, MiWEndo enhances diagnostic accuracy and aims to transform colorectal cancer screening.
Protego
Protego empowers billing teams with AI-driven tools to prevent and appeal denied medical claims. Founded after a personal experience with denied claims, Protego helps provider RCM teams ensure that patients are not left with unfair medical bills.
Twistomy
Twistomy is a medical device startup reimagining ostomy care through a novel, minimally invasive continent ostomy system that eliminates the need for external pouches. Twistomy’s low-profile design enhances comfort, hygiene and patient independence while supporting safety and regulatory validation.
Amplified Sciences
Amplified Sciences is an in-vitro diagnostics company leveraging an ultra-sensitive molecular sensing platform to develop innovative tests that empower clinicians to diagnose, treat and monitor complex diseases with greater confidence. Its lead assay, PanCystPro, is a highly accurate risk stratification tool that helps rule out malignancy in patients with pancreatic cystic lesions — a known precursor to pancreatic cancer — while requiring 50 times less sample volume than competing technologies.
Lura Health
Lura Health is developing a next-generation wearable health sensor that uses saliva instead of blood for continuous health monitoring. The company leverages the diagnostic power of saliva — a multi-billion dollar industry — for continuous monitoring rather than one-time tests.
Neurogut
Neurogut has developed the BioAnatoner System, a breakthrough, clinically proven biofeedback therapy device that treats major pelvic floor disorders, including dyssynergia/constipation and fecal and urinary incontinence. Designed for both clinic and home use, the BioAnatoner combines clinical efficacy with accessibility, creating a scalable solution in a large, underserved market. With plans to launch in 2026, Neurogut aims to transform care for more than 100 million people in the U.S.
Prevenotics
Prevenotics aims to shift GI cancer care from reactive treatment to proactive prevention with our AI-powered software. Our platform provides real-time analysis for various GI cancers and pre-cancerous lesions. Critically, its unique focus on gastric health empowers patients to actively manage their risk from the earliest precancerous stages, turning diagnostic insights into actionable, preventive surveillance management.
Flow Therapeutics
Flow Therapeutics is developing the first targeted therapy for intestinal fibrosis in Crohn’s disease, aiming to improve patients’ quality of life by preventing recurrent strictures. Its lead candidate, a sustained-release formulation of sulconazole nanocrystals (Sul-NC) delivered endoscopically, directly targets the fibrotic process that causes stricture recurrence. By addressing the root mechanism of stricture formation, Sul-NC has the potential to reduce repeat interventions, lower healthcare costs and ease the long-term burden on patients and healthcare systems.
GI Transit
GI Transit was established in San Diego, California, as an R&D company with a special focus on diagnostic devices for the upper GI tract. Innovations from GI Transit are based on novel ideas from active participation in medical research to provide deep insight into GI physiology and pathophysiology. GI Bionics has several medical devices in the pipeline including the ingestible EsoTrackR.
About the AGA Institute
The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, AGA represents members from around the globe who are involved in all aspects of the science, practice, and advancement of gastroenterology. The AGA Institute administers the practice, research, and educational programs of the organization.
About MATTER
At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 1,000 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.